COVID-19, steroids and other immunomodulators: The jigsaw is not complete.
作者信息
Rello Jordi, Waterer Grant W, Bourdiol Alexandre, Roquilly Antoine
机构信息
Centro de Investigación Biomedica en Red (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain; Clinical Research, CHU Nîmes, Université Montpellier-Nîmes, 30029 NÎMES, France.
University of Western Australia and Northwestern University, Chicago, USA.
出版信息
Anaesth Crit Care Pain Med. 2020 Dec;39(6):699-701. doi: 10.1016/j.accpm.2020.10.011. Epub 2020 Oct 25.
Abstract
摘要
相似文献
1
COVID-19, steroids and other immunomodulators: The jigsaw is not complete.新型冠状病毒肺炎、类固醇及其他免疫调节剂：拼图尚未完成。
Anaesth Crit Care Pain Med. 2020 Dec;39(6):699-701. doi: 10.1016/j.accpm.2020.10.011. Epub 2020 Oct 25.
2
[Corticosteroids in intensive care medicine].[重症医学中的皮质类固醇]
Dtsch Med Wochenschr. 2024 Jun;149(12):714-718. doi: 10.1055/a-2128-5319. Epub 2024 May 23.
3
Tocilizumab for hospitalized patients with COVID-19.托珠单抗用于住院的新冠肺炎患者。
CMAJ. 2021 Apr 12;193(15):E521. doi: 10.1503/cmaj.210066. Epub 2021 Mar 9.
4
Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.基于 COVID-19、其他冠状病毒感染、流感、社区获得性肺炎和急性呼吸窘迫综合征的证据评估 COVID-19 中皮质类固醇的疗效和安全性：系统评价和荟萃分析。
CMAJ. 2020 Jul 6;192(27):E756-E767. doi: 10.1503/cmaj.200645. Epub 2020 May 14.
5
The Use of High-Dose Corticosteroids Versus Low-Dose Corticosteroids With and Without Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.COVID-19 急性呼吸窘迫综合征中高剂量与低剂量皮质类固醇联合或不联合托珠单抗的应用。
Ann Pharmacother. 2023 Jan;57(1):5-15. doi: 10.1177/10600280221094571. Epub 2022 May 19.
6
Audio Interview: Tocilizumab and Covid-19.音频访谈：托珠单抗与新冠病毒
N Engl J Med. 2020 Oct 22;383(17):e114. doi: 10.1056/NEJMe2032051.
7
High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial.COVID-19 继发急性呼吸窘迫综合征的高剂量地塞米松治疗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Aug 26;21(1):743. doi: 10.1186/s13063-020-04646-y.
8
Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.2019冠状病毒病患者使用全身性类固醇：利弊，内分泌学视角
J Endocrinol Invest. 2021 Apr;44(4):873-875. doi: 10.1007/s40618-020-01325-2. Epub 2020 Jun 8.
9
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.直面争议：白细胞介素-6 与 COVID-19 细胞因子风暴综合征。
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.
10
Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.COVID-19 患者的支气管肺泡炎症：与临床结局的相关性。
BMC Pulm Med. 2020 Nov 16;20(1):301. doi: 10.1186/s12890-020-01343-z.
引用本文的文献
1
Interleukin-6 and granulocyte colony-stimulating factor as predictors of the prognosis of influenza-associated pneumonia.白细胞介素-6 和粒细胞集落刺激因子作为流感相关性肺炎预后的预测因子。
BMC Infect Dis. 2022 Apr 6;22(1):343. doi: 10.1186/s12879-022-07321-6.
2
Covid-19 and leptospirosis, pulmonary involvement and response to steroids: A comparative observational study from a rural Tertiary care center in Kerala.新型冠状病毒肺炎与钩端螺旋体病、肺部受累情况及对类固醇的反应：一项来自喀拉拉邦农村三级医疗中心的比较性观察研究
J Family Med Prim Care. 2022 Jan;11(1):294-298. doi: 10.4103/jfmpc.jfmpc_1414_21. Epub 2022 Jan 31.
3
Relation Between Body Composition, Systemic Inflammatory Response, and Clinical Outcomes in Patients Admitted to an Urban Teaching Hospital with COVID-19.城市教学医院 COVID-19 患者的身体成分、全身炎症反应与临床结局的关系。
J Nutr. 2021 Aug 7;151(8):2236-2244. doi: 10.1093/jn/nxab142.
4
Corticosteroid therapy in COVID-19 patients: Don't forget venous thromboembolism.新冠病毒肺炎患者的皮质类固醇治疗：不要忘记静脉血栓栓塞症。
Anaesth Crit Care Pain Med. 2021 Feb;40(1):100783. doi: 10.1016/j.accpm.2020.11.003. Epub 2020 Nov 19.
本文引用的文献
1
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
2
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
3
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.COVID-19 重症患者早期使用托珠单抗治疗与死亡率的关联。
JAMA Intern Med. 2021 Jan 1;181(1):41-51. doi: 10.1001/jamainternmed.2020.6252.
4
Sarilumab use in severe SARS-CoV-2 pneumonia.托珠单抗用于严重新型冠状病毒肺炎
EClinicalMedicine. 2020 Oct;27:100553. doi: 10.1016/j.eclinm.2020.100553. Epub 2020 Oct 2.
5
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.羟考酮治疗对严重 COVID-19 患者死亡率和器官支持的影响：REMAP-CAP COVID-19 皮质类固醇随机临床试验。
JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
6
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响：CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
7
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.COVID-19 重症患者中氢化可的松对 21 天死亡率或呼吸支持的影响：一项随机临床试验。
JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761.
8
Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial.甲泼尼龙辅助治疗 2019 年冠状病毒病（COVID-19；METCovid）住院患者：一项随机、双盲、IIb 期、安慰剂对照试验。
Clin Infect Dis. 2021 May 4;72(9):e373-e381. doi: 10.1093/cid/ciaa1177.
9
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.COVID-19 合并 2 型糖尿病患者的血糖控制与结局的相关性。
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3. doi: 10.1016/j.cmet.2020.04.021. Epub 2020 May 1.
10
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.严重 COVID-19 中的细胞因子释放综合征：白细胞介素-6 受体拮抗剂托珠单抗可能是降低死亡率的关键。
Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.
Zotero 插件